It’s time to revisit billing for Medicare Part B drugs. A proposed demonstration project that every urologist should be aware of, a change in the “brown bag” rules since our last publication, and a continued loss of income by many offices are making the purchase and delivery of drugs less palatable for urology offices.
We should also add to that list the increased number of high-priced drugs available to treat urologic problems. It is a conundrum created under a difficult pressure to increase the care provided to more people of Medicare age under a shrinking budget.
Some good news and we all like good news. Urology practices continue to navigate the onslaught of federal and private payer administrative and financial challenges while delivering quality care and services. Working with numerous group practices around the country and speaking with many practice leaders I see firsthand the impact on both private practice and employed physicians. Every medical group today is challenged by the staggering lists of competencies required to survive the reality of new value-based payment methodology while maximizing current fee-for-service revenues. The healthcare landscape is clearly different from the one that existed even five years ago and the financial impact on physician net income is real. Today’s healthcare leaders must navigate an unprecedented era of change including healthcare reform driven mandates and the rapid advancement in healthcare technology driven solutions.